Literature DB >> 8982034

Reversible bone marrow depression by high-dose piperacillin/tazobactam.

G Ruiz-Irastorza1, G Barreiro, C Aguirre.   

Abstract

Bone marrow toxicity, mainly neutropenia, has been described as an uncommon secondary effect of most beta-lactams, and it is usually related to large cumulative doses. Although previously described for piperacillin, no cases of marrow depression caused by piperacillin/tazobactam have been reported to date. We report a case of reversible pancytopenia, with evidence of bone marrow depression, which occurred after a 17 d course of piperacillin/tazobactam. The drug was given to an underweight 18-year-old woman, at the usual dosage of 4/0.5 g three times a day. We stress the need for reducing the recommended dosage when treating underweight adult patients, and also of monitoring haematological parameters during prolonged treatments.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982034     DOI: 10.1046/j.1365-2141.1996.d01-1952.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  A case of probable piperacillin/tazobactam-induced bone marrow suppression in a pregnant woman.

Authors:  Samah ElSalem; Shaza Elawad; Afif Ahmed; Muna AlSaadi; Moza AlHail
Journal:  Eur J Hosp Pharm       Date:  2017-10-21

Review 2.  Systematic review of piperacillin-induced neutropenia.

Authors:  Marc H Scheetz; June M McKoy; Jorge P Parada; Benjamin Djulbegovic; Dennis W Raisch; Paul R Yarnold; Jessica Zagory; Steve Trifilio; Rita Jakiche; Frank Palella; Adam Kahn; Kevin Chandler; Charles L Bennett
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Risk of Neutropenia in Adults Treated with Piperacillin-Tazobactam or Cefazolin: A Retrospective Cohort Study.

Authors:  Marie-Pier Roy; Frédéric Calon; David Simonyan; Luc Bergeron
Journal:  Can J Hosp Pharm       Date:  2022-07-04

4.  Piperacillin/tazobactam Induced Myelosuppression.

Authors:  Kirsty Wai Chung Lee; Kai Ming Chow; Natalie Pui Ha Chan; Angeline Oi Shan Lo; Cheuk Chun Szeto
Journal:  J Clin Med Res       Date:  2009-03-24

5.  Assessing the Effect of Piperacillin/Tazobactam on Hematological Parameters in Patients Admitted with Moderate or Severe Foot Infections.

Authors:  Will Fry; Sean McCafferty; Catherine Gooday; Ian Nunney; Ketan K Dhatariya
Journal:  Diabetes Ther       Date:  2018-01-04       Impact factor: 2.945

6.  Hematologic Adverse Effects of Prolonged Piperacillin-Tazobactam Use in Adults

Authors:  Aysun Benli; Serap Şimşek-Yavuz; Seniha Başaran; Atahan Çağatay; Halit Özsüt; Haluk Eraksoy
Journal:  Turk J Haematol       Date:  2018-06-01       Impact factor: 1.831

7.  Myelodysplastic syndrome in a case of new-onset pancytopenia.

Authors:  Ian Lancaster; Deep Patel; Vikas Sethi; Weston Connelly; Joseph Namey
Journal:  Clin Case Rep       Date:  2022-03-03

8.  Piperacillin induced bone marrow suppression: a case report.

Authors:  Ashish Kumar; Gourdas Choudhuri; Rakesh Aggarwal
Journal:  BMC Clin Pharmacol       Date:  2003-06-05

9.  Tazobactam and piperacillin-induced thrombocytopenia: A case report.

Authors:  Hong Chen; Zhen Fan; Fei Guo; Yumin Yang; Jie Li; Jie Zhang; Yudan Wang; Jianwei LE; Zhiyu Wang; Jianhua Zhu
Journal:  Exp Ther Med       Date:  2016-02-09       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.